Why a US-funded vaccine trial on babies was cancelled in Guinea-Bissau

A US-funded clinical trial for a hepatitis vaccine targeting infants in Guinea-Bissau has been halted following significant controversy. The decision to stop the study came after it was widely criticized by observers who described the initiative as unethical and neocolonial. A primary point of contention was the trial’s design, which involved withholding the vaccine from half of the participating babies. Critics argued that this methodology was unacceptable, asserting that the project would effectively deny critical immunization to thousands of infants who needed protection against the disease.

While the specific motivations behind the halt are not detailed in the available reports, the consensus among experts and commentators highlights the ethical implications of the study’s structure. The backlash focused on the moral burden of exposing vulnerable children to risk without providing them with the potential benefits of the vaccine. The incident has sparked broader discussions regarding the standards of medical research in developing nations and the responsibilities of international funders. Although the sources agree on the general nature of the criticism and the outcome of the trial, they do not provide conflicting details on the events themselves, instead reinforcing the narrative that the trial was terminated due to its perceived lack of ethical integrity and the harm it posed to the infant population.

Compiled from: BBC News · Al Jazeera

This summary was written by AI from the information reported by the sources above and may contain errors. Check the sources for certainty.